Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorDANTAS, Naiara C. B.
dc.contributor.authorSOARES, Carlos E. L.
dc.contributor.authorMARTINS, Manoel R. A.
dc.contributor.authorLOURENCO JR., Delmar M.
dc.contributor.authorQUIDUTE, Ana R. P.
dc.identifier.citationFRONTIERS IN ENDOCRINOLOGY, v.10, article ID 582, 9p, 2019
dc.description.abstractContext: Overall, giant prolactinomas are rare tumors (4%), especially those larger than 60 mm (1%). Despite the predominance of macroadenoma documented in multiple endocrine neoplasia type 1 (MEN1)-related prolactinoma, only three giant prolactinoma cases were described so far (size > 40 mm and prolactin > 1,000 ng/mL). None of them was larger than 60 mm or presented hydrocephalus or intracranial hypertension (ICH) as initial manifestation of MEN1. Case Description: A 21-years-old man presented with ICH as the first clinical manifestation of MEN1. He harbored a MEN1 germline mutation but refused periodic vigilance after normal hormonal screening at age 14 years. During investigation, magnetic resonance imaging (MRI) of the skull showed an expansive sellar/parasellar lesion (75 x 44 x 36 mm) with moderate to severe supratentorial obstructive hydrocephalus and an extremely high serum prolactin (PRL) of 10,800 ng/mL, without combined hypersecretion of other pituitary hormones. He was diagnosed with giant prolactinoma, and cabergoline was initiated. The patient evolved with early improvement of clinical complaints for hydrocephalus and ICH and PRL reached normal values (11 ng/mL) in association with significant tumoral shrinkage after 18 months on cabergoline. After 2 months of cabergoline, cerebrospinal fluid leakage was diagnosed and corrective surgery was provided. The mean dose of cabergoline was 3 mg/week throughout treatment. Conclusion: We reported the first case with hydrocephalus and ICH as the initial clinical manifestation of a giant prolactinoma in MEN1. From our knowledge, this is the largest MEN1-related prolactinoma reported so far. Notably, all four MEN1-related giant prolactinomas cases reported were younger than 21 years strengthening the importance to routine MEN1 genetic testing for prolactinoma in this age group. Also, they all had initial effective response with dopamine agonist ensuring this drug as first-line treatment for MEN1-related giant prolactinoma. However, the scarce number of treated patients and progression of cabergoline resistance in two of them suggest strict surveillance.eng
dc.description.sponsorshipFAPESP [2013/19810-2, 2016/07504-2]
dc.publisherFRONTIERS MEDIA SAeng
dc.relation.ispartofFrontiers in Endocrinology
dc.subjectgiant prolactinomaeng
dc.subjectdopaminergic agonisteng
dc.subjectpituitary adenomaeng
dc.subjectobstructive hydrocephaluseng
dc.subjectintracranial hypertensioneng
dc.subjectmultiple endocrine neoplasia type 1eng
dc.subject.otherclinical presentationeng
dc.subject.otherobstructive hydrocephaluseng
dc.titleGiant Prolactinoma Causing Hydrocephalus and Intracranial Hypertension as First Manifestations of Multiple Endocrine Neoplasia Type 1eng
dc.rights.holderCopyright FRONTIERS MEDIA SAeng
dc.subject.wosEndocrinology & Metabolismeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng, Naiara C. B.:Univ Fed Ceara, Walter Cantidio Univ Hosp, Fortaleza, Ceara, Brazil, Carlos E. L.:Fed Univ Ceara UFC, Fac Med, Drug Res & Dev Ctr NPDM, Fortaleza, Ceara, Brazil, Manoel R. A.:Univ Fed Ceara, Walter Cantidio Univ Hosp, Fortaleza, Ceara, Brazil, Ana R. P.:Univ Fed Ceara, Walter Cantidio Univ Hosp, Fortaleza, Ceara, Brazil; Fed Univ Ceara UFC, Fac Med, Drug Res & Dev Ctr NPDM, Fortaleza, Ceara, Brazil
hcfmusp.relation.referenceAcharya SV, 2010, ENDOCR PRACT, V16, P42, DOI 10.4158/EP09221.OReng
hcfmusp.relation.referenceAcharya SV, 2009, PITUITARY, V12, P186, DOI 10.1007/s11102-008-0149-8eng
hcfmusp.relation.referenceAlkatari S, 2012, CLIN MED INSIGHT-CAS, V5, P115, DOI 10.4137/CCRep.S9675eng
hcfmusp.relation.referenceCackett P, 2012, FUTURE ONCOL, V8, P1621, DOI [10.2217/FON.12.149, 10.2217/fon.12.149]eng
hcfmusp.relation.referenceCannavo S, 2003, CLIN ENDOCRINOL, V58, P519, DOI 10.1046/j.1365-2265.2003.01748.xeng
hcfmusp.relation.referenceCarvalho RA, 2018, EUR J ENDOCRINOL, V179, P391, DOI 10.1530/EJE-18-0430eng
hcfmusp.relation.referenceChattopadhyay Arijit, 2005, Pituitary, V8, P147, DOI 10.1007/s11102-005-5111-4eng
hcfmusp.relation.referenceChentli Farida, 2015, Indian J Endocrinol Metab, V19, P359, DOI 10.4103/2230-8210.152771eng
hcfmusp.relation.referenceColao A, 1998, J CLIN ENDOCR METAB, V83, P2777, DOI 10.1210/jc.83.8.2777eng
hcfmusp.relation.referenceCuny T, 2013, EUR J ENDOCRINOL, V168, P533, DOI 10.1530/EJE-12-0763eng
hcfmusp.relation.referencede Laat JM, 2015, J CLIN ENDOCR METAB, V100, P3288, DOI 10.1210/JC.2015-2015eng
hcfmusp.relation.referenceDelgrange E, 2014, EUR J ENDOCRINOL, V170, P31, DOI 10.1530/EJE-13-0503eng
hcfmusp.relation.referenceDrori-Herishanu L, 2009, HORM METAB RES, V41, P630, DOI 10.1055/s-0029-1216358eng
hcfmusp.relation.referenceFalchetti A, 2017, F1000RESEARCH, V6, P73, DOI 10.12688/F1000RESEARCH.7230.1eng
hcfmusp.relation.referenceGan HW, 2015, INT J PEDIATR ENDOCR, DOI 10.1186/s13633-015-0011-5eng
hcfmusp.relation.referenceGillam MP, 2006, ENDOCR REV, V27, P485, DOI 10.1210/er.2005-9998eng
hcfmusp.relation.referenceGoudet P, 2015, J CLIN ENDOCR METAB, V100, P1568, DOI 10.1210/jc.2014-3659eng
hcfmusp.relation.referenceGoudet P, 2010, WORLD J SURG, V34, P249, DOI 10.1007/s00268-009-0290-1eng
hcfmusp.relation.referenceGREBE SKG, 1992, NEW ZEAL MED J, V105, P129eng
hcfmusp.relation.referenceHoffmann A, 2018, EUR J PEDIATR, V177, P125, DOI 10.1007/s00431-017-3042-5eng
hcfmusp.relation.referenceIglesias P, 2004, AGE AGEING, V33, P410, DOI 10.1093/ageing/afh108eng
hcfmusp.relation.referenceIglesias P, 2018, HORM METAB RES, V50, P791, DOI 10.1055/a-0752-0741eng
hcfmusp.relation.referenceLABAUGE R, 1982, REV NEUROL, V138, P149eng
hcfmusp.relation.referenceLemos MC, 2008, HUM MUTAT, V29, P22, DOI 10.1002/humu.20605eng
hcfmusp.relation.referenceLiu Y, 2015, CHILD NERV SYST, V31, P909, DOI 10.1007/s00381-015-2679-5eng
hcfmusp.relation.referenceLourenco DM, 2008, EUR J ENDOCRINOL, V159, P259, DOI 10.1530/EJE-08-0153eng
hcfmusp.relation.referenceMaiter D, 2014, EUR J ENDOCRINOL, V170, pR213, DOI 10.1530/EJE-14-0013eng
hcfmusp.relation.referenceMascarell S, 2007, PITUITARY, V10, P95, DOI 10.1007/s11102-007-0009-yeng
hcfmusp.relation.referenceMoraes AB, 2013, CLIN ENDOCRINOL, V79, P447, DOI 10.1111/cen.12242eng
hcfmusp.relation.referenceMuniz Lourenco D, 2007, CLINICS, V62, P465, DOI 10.1590/S1807-59322007000400014eng
hcfmusp.relation.referenceMURPHY FY, 1987, AM J MED, V83, P995, DOI 10.1016/0002-9343(87)90668-1eng
hcfmusp.relation.referenceOBrien T, 1996, NEUROSURGERY, V39, P273, DOI 10.1097/00006123-199608000-00008eng
hcfmusp.relation.referenceOiwa A, 2002, ENDOCR J, V49, P635, DOI 10.1507/endocrj.49.635eng
hcfmusp.relation.referencePERANI D, 1984, J COMPUT ASSIST TOMO, V8, P131, DOI 10.1097/00004728-198402000-00027eng
hcfmusp.relation.referenceRodrigues KC, 2017, THYROID, V27, P693, DOI 10.1089/thy.2016.0148eng
hcfmusp.relation.referenceSaeki N, 1998, ENDOCR J, V45, P529, DOI 10.1507/endocrj.45.529eng
hcfmusp.relation.referenceSalenave S, 2015, J CLIN ENDOCR METAB, V100, P1177, DOI 10.1210/jc.2014-3670eng
hcfmusp.relation.referenceSarkar PK, 2001, AGE AGEING, V30, P426, DOI 10.1093/ageing/30.5.426eng
hcfmusp.relation.referenceScarone P, 2006, J NEURO-ONCOL, V76, P51, DOI 10.1007/s11060-005-2319-0eng
hcfmusp.relation.referenceSchofl Christof, 2002, Pituitary, V5, P261, DOI 10.1023/A:1025334001748eng
hcfmusp.relation.referenceShimon I, 2016, PITUITARY, V19, P429, DOI 10.1007/s11102-016-0723-4eng
hcfmusp.relation.referenceShrivastava RK, 2002, J NEUROSURG, V97, P299, DOI 10.3171/jns.2002.97.2.0299eng
hcfmusp.relation.referenceSteele CA, 2010, EUR J ENDOCRINOL, V163, P515, DOI 10.1530/EJE-10-0519eng
hcfmusp.relation.referenceStratakis CA, 2010, CLIN GENET, V78, P457, DOI 10.1111/j.1399-0004.2010.01406.xeng
hcfmusp.relation.referenceSubasinghe CJ, 2018, CASE REP ENDOCRINOL, DOI 10.1155/2018/2875074eng
hcfmusp.relation.referenceTasma H, 2011, ACTA ENDOCRINOL-COP, V7, P95, DOI [10.4183/aeb.2011.95, DOI 10.4183/AEB.2011.95]eng
hcfmusp.relation.referenceTeh BT, 1998, J CLIN ENDOCR METAB, V83, P2621, DOI 10.1210/jc.83.8.2621eng
hcfmusp.relation.referenceThakker RV, 2012, J CLIN ENDOCR METAB, V97, P2990, DOI 10.1210/jc.2012-1230eng
hcfmusp.relation.referenceToledo RA, 2007, CLIN ENDOCRINOL, V67, P377, DOI 10.1111/j.1365-2265.2007.02895.xeng
hcfmusp.relation.referenceVannucci L, 2018, ENDOCRINE, V59, P438, DOI 10.1007/s12020-017-1322-5eng
hcfmusp.relation.referenceVerges B, 2002, J CLIN ENDOCR METAB, V87, P457, DOI 10.1210/jc.87.2.457eng
hcfmusp.relation.referenceWu ZB, 2006, J NEUROSURG, V104, P54, DOI 10.3171/jns.2006.104.1.54eng
hcfmusp.relation.referenceYu Chonjiang, 2005, Pituitary, V8, P61, DOI 10.1007/s11102-005-5087-0eng
hcfmusp.relation.referenceZikel OM, 1999, MAYO CLIN PROC, V74, P475eng
Appears in Collections:

Artigos e Materiais de Revistas Científicas - HC/ICESP
Instituto do Câncer do Estado de São Paulo - HC/ICESP

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - LIM/25
LIM/25 - Laboratório de Endocrinologia Celular e Molecular

Files in This Item:
File Description SizeFormat 
art_DANTAS_Giant_Prolactinoma_Causing_Hydrocephalus_and_Intracranial_Hypertension_as_2019.PDFpublishedVersion (English)881.54 kBAdobe PDFThumbnail

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.